Related Experiment Video
Updated: Feb 11, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Biagio Ricciuti1, Andrea De Giglio2, Carmen Mecca3
1Department of Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Piazzale L. Severi n. 1, 06132, Perugia, Italy. biagio.ricciuti@gmail.com.
Abstract:
Anaplastic lymphoma kinase (ALK) rearrangements represent the molecular driver of a subset of non-small cell lung cancers (NSCLCs). Despite the initial response, virtually all ALK-positive patients develop an acquired resistance to the ALK inhibitor crizotinib, usually within 12 months. Several next-generation ALK inhibitors have been developed in order to overcome crizotinib limitation, providing an unprecedented survival for this subset of patients. The aim of this review to summarize the current knowledge on ALK tyrosine kinase inhibitors (TKIs) in the treatment of advanced ALK-positive NSCLC, focusing on the role of novel ALK inhibitors in this setting. In addition, we will discuss their role in the pharmacological management of ALK-positive brain metastasis. Next-generation ALK inhibitors showed an impressive clinical activity in ALK-positive NSCLC, also against the sanctuary site of CNS. Sequential therapy with ALK TKIs appears to be effective in patients who fail a first ALK TKI and translates in clinically meaningful benefit. However, these agents display different activity profiles against crizotinib resistance mutation; therefore re-genotyping the disease at progression in order to administer the right TKI to the right patient is going to be necessary to correctly tailor the treatment. To avoid repeated invasive procedure, noninvasive methods to detect and monitor ALK rearrangement are under clinical investigation.
Insights
Next-generation anaplastic lymphoma kinase (ALK) inhibitors offer improved survival for ALK-positive non-small cell lung cancer (NSCLC) patients, including those with brain metastases. Re-testing for ALK mutations at progression is crucial for personalized treatment selection.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) rearrangements drive a subset of non-small cell lung cancers (NSCLCs).
- Acquired resistance to the first-generation ALK inhibitor crizotinib develops in most ALK-positive NSCLC patients within a year.
- Next-generation ALK inhibitors have been developed to overcome crizotinib resistance and improve patient outcomes.
Purpose of the Study:
- To review current knowledge on ALK tyrosine kinase inhibitors (TKIs) for advanced ALK-positive NSCLC.
- To focus on the role of novel ALK inhibitors in treating ALK-positive NSCLC.
- To discuss the management of ALK-positive brain metastases with these agents.
Main Methods:
- Literature review of ALK tyrosine kinase inhibitors (TKIs) in advanced ALK-positive NSCLC.
- Analysis of clinical activity, including efficacy against central nervous system (CNS) metastases.
- Evaluation of sequential TKI therapy and the necessity of re-genotyping at progression.
Main Results:
- Next-generation ALK inhibitors demonstrate significant clinical activity in ALK-positive NSCLC, including CNS metastases.
- Sequential therapy with ALK TKIs shows efficacy in patients who have progressed on prior ALK TKI treatment.
- Different ALK inhibitors exhibit varying activity against crizotinib resistance mutations.
Conclusions:
- Personalized treatment selection based on re-genotyping at disease progression is essential due to differing activity profiles of ALK TKIs against resistance mutations.
- Non-invasive methods for detecting and monitoring ALK rearrangements are under investigation to avoid repeated invasive procedures.
Related Concept Videos
Lung Capacity
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Uncertainty in Measurement: Accuracy and Precision
Microorganisms in Medicine and Therapeutics
Accuracy and Precision

